A Phase 3 interventional study of Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX and SYMBICORT TURBOHALER budesonide and formoterol fumarate in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 74 sites in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-22.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. — none open to participants now, 1 under way, 1 of them phase 3. Asthma · Teva Pharmaceutical Industries, Ltd..
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 16th largest by enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2014, is one of 30 in phase 3, and was the 29th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →None of the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. is open now. The open studies under Asthma, anywhere →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 485 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 317 across the 51 interventional studies, 1,025 across the 2 observational. Of the 52 that completed or were terminated, 36 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
1 of the studies in Asthma by Teva Pharmaceutical Industries, Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is conducted to assess whether training participants on proper use of BF SPIROMAX and Symbicort TURBOHALER will improve their device-handling technique and potentially improve their treatment outcome, that is, better asthma control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female and of childbearing potential, the participant must have a negative urine pregnancy test.
Exclusion Criteria:
The participant has a known allergy or severe sensitivity to the constituents of the study drugs (SPIROMAX or TURBOHALER),for example, to lactose or to milk protein.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be trained on the proper use of empty Spiromax followed by empty Turbohaler devices.
Participants will be trained on the proper use of empty Turbohaler followed by empty Spiromax devices.
Participants who have currently received 800 to 1000 micrograms (μg) beclomethasone-equivalent inhaled corticosteroid (ICS) per day will receive budesonide/formoterol twice daily using the BF Spiromax 160/4.5 device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 640 μg and 18 μg, respectively. Participants who have currently received 1600 to 2000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the BF Spiromax 320/9 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 1280 μg and 36 μg, respectively.
Drug: Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX
Participants who have currently received 800 to 1000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 800 μg and 24 μg respectively. Participants who have currently received 1600 to 2000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 1600 μg and 48 μg respectively.
Drug: SYMBICORT TURBOHALER budesonide and formoterol fumarate
SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 μg)
Also known as: SPIROMAX®
SYMBICORT® TURBOHALER® (200/6 and 400/12 μg)
Also known as: SYMBICORT®, TURBOHALER®
Stage 1: Percentage of Participants Achieving Device Mastery
Device mastery was defined as absence of healthcare professional (HCP)-observed errors by the end of Step 3 of a 6-step standardized device training protocol for empty Spiromax compared to empty Turbohaler. The 6 steps of device training protocol were: Step 1 - Intuitive use; Step 2 - Patient information leaflet; Step 3 - Instructional video; Step 4 - HCP tuition; Step 5 - HCP tuition (1st repeat); Step 6 - HCP tuition (2nd repeat).
Time frame: Baseline (Day 1)
Stage 2: Percentage of Participants Maintaining Device Mastery
Maintenance of device mastery was defined as absence of HCP-observed errors after 12 weeks of device use.
Time frame: Baseline up to Week 12
Stage 1: Percentage of Participants Achieving Device Mastery by Step 1
The number of participants achieving device mastery by Step 1 (no training/intuitive use) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.
Time frame: Day 1
Stage 1: Percentage of Participants Achieving Device Mastery by Step 2
The number of participants achieving device mastery by Step 2 (patient device information leaflet) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.
Time frame: Day 1
Stage 1: Number of Steps Taken to Achieve Device Mastery
Time frame: Baseline (Day 1)
Stage 1: Number of Nurse-Observed Errors
Time frame: Day 1
Stage 1: Patient Satisfaction and Preference Questionnaire (PASAPQ) Total Score
The PASAPQ is a multi-item measure of inhalation device satisfaction and preference designed specifically for participants with asthma and chronic obstructive pulmonary disease. The PASAPQ includes a total of 14 device satisfaction items, including an overall satisfaction item. The total score was the sum of the 13 items related to performance and convenience domains (7 items for performance domain: Questions 1-5, 10-11, and 6 items for convenience domain: Questions 6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction.
Time frame: Baseline (Day 1)
Composite Endpoint: Stage 2: Total Number of Observed Errors (Nurse and Technology [Vitalograph Pneumotrac Spirometer])
Composite score calculated as the sum of nurse observed errors and technology-observed errors.
Time frame: Baseline up to Week 12
Stage 2: Number of Technology-Observed Errors (Vitalograph Pneumotrac Spirometer)
Time frame: Week 12
Stage 2: Total Number of Handling Errors
Total number of device handling errors included HCP observed errors and technology observed errors.
Time frame: Baseline up to Week 12
Stage 2: Change in Handling Errors From Stage 1 to Stage 2
The difference in the number of handling errors identified after participant training using the patient device information leaflet at stage 1 and after 12 weeks of treatment (end of stage 2).
Time frame: Baseline (Day 1), Week 12
Stage 2: Number of Participants In Pre-specified Treatment Adherence Categories (Assessed by Device Dose Counters)
Treatment adherence was categorized (as less than or equal to 50%, 51%-70%, 71%-99%, and 100%) and compared across treatment groups using a chi-square test.
Time frame: Baseline up to Week 12
Stage 2: Change From Baseline in 6-Item Asthma Control Questionnaire (ACQ) (Excluding Forced Expiratory Volume in 1 Second [FEV1] Question) Score at Weeks 4, 8, and 12
The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted forced expiratory volume in 1 second (FEV1) on a 7-point scale (0 to 6). The score is the mean of the first 6 questions (excluding the FEV1 question), generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 4, 8, and 12
Stage 2: Change From Baseline in 7-Item ACQ
The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.
Time frame: Baseline, Week 12
Stage 2: Time to First Treatment Failure
Time to treatment failure was defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection.
Time frame: Baseline up to Week 12
Stage 2: Number of Participants With Severe Asthma Exacerbations
Severe asthma exacerbation was defined as a hospitalization or emergency room attendance for asthma, or an acute course of oral corticosteroids (OCS).
Time frame: Week 12
Stage 2: Impact of Maintaining Device Mastery on Time to Treatment Failure
The impact of maintaining device mastery on time to treatment failure (defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection) was assessed by comparing the time to treatment failure for participants with and without device mastery. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.
Time frame: Baseline Up to Week 12
Stage 2: Impact of Maintaining Device Mastery on Asthma Control Questionnaire Score
The impact of maintaining device mastery on asthma control was assessed by comparing the 7-item ACQ scores for participants with and without device mastery. The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.
Time frame: Baseline Up to Week 12
Number of Participants With Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
Time frame: Baseline up to Week 12
| Milestone | Stage 1: Empty Spiromax Followed by Empty Turbohaler | Stage 1: Empty Turbohaler Followed by Empty Spiromax | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|---|---|
| Started | 243 | 242 | 0 | 0 |
| Full analysis set | 240 | 241 | 0 | 0 |
| Completed | 240 | 241 | 0 | 0 |
| Not completed | 3 | 1 | 0 | 0 |
| Withdrew: Withdrawals during stage 1 were not captured | 3 | 1 | 0 | 0 |
| Milestone | Stage 1: Empty Spiromax Followed by Empty Turbohaler | Stage 1: Empty Turbohaler Followed by Empty Spiromax | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|---|---|
| Started | 0 | 0 | 197 | 197 |
| Received at least 1 dose of study drug | 0 | 0 | 197 | 197 |
| Full analysis set | 0 | 0 | 151 | 154 |
| Completed | 0 | 0 | 144 | 141 |
| Not completed | 0 | 0 | 53 | 56 |
| Withdrew: Adverse event | 0 | 0 | 12 | 20 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 20 | 20 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 1 |
| Withdrew: Other than specified | 0 | 0 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 15 | 10 |
Device mastery was defined as absence of healthcare professional (HCP)-observed errors by the end of Step 3 of a 6-step standardized device training protocol for empty Spiromax compared to empty Turbohaler. The 6 steps of device training protocol were: Step 1 - Intuitive use; Step 2 - Patient information leaflet; Step 3 - Instructional video; Step 4 - HCP tuition; Step 5 - HCP tuition (1st repeat); Step 6 - HCP tuition (2nd repeat).
| percentage of participants | Stage 1: Empty Spiromax | Stage 1: Empty Turbohaler |
|---|---|---|
| Stage 1: Percentage of Participants Achieving Device Mastery | 94.4 | 86.9 |
Maintenance of device mastery was defined as absence of HCP-observed errors after 12 weeks of device use.
| percentage of participants | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| Stage 2: Percentage of Participants Maintaining Device Mastery | 58.9 | 53.2 |
The number of participants achieving device mastery by Step 1 (no training/intuitive use) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.
| Percentage of participants | Stage 1: Empty Spiromax | Stage 1: Empty Turbohaler |
|---|---|---|
| Stage 1: Percentage of Participants Achieving Device Mastery by Step 1 | 33.3 | 11.4 |
The number of participants achieving device mastery by Step 2 (patient device information leaflet) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.
| Percentage of participants | Stage 1: Empty Spiromax | Stage 1: Empty Turbohaler |
|---|---|---|
| Stage 1: Percentage of Participants Achieving Device Mastery by Step 2 | 80.2 | 64.0 |
| steps | Stage 1: Empty Spiromax | Stage 1: Empty Turbohaler |
|---|---|---|
| Stage 1: Number of Steps Taken to Achieve Device Mastery | 1 (0 to 12) | 2 (0 to 15) |
| Errors | Stage 1: Empty Spiromax | Stage 1: Empty Turbohaler |
|---|---|---|
| Stage 1: Number of Nurse-Observed Errors | 1.91 ± 0.89 | 2.36 ± 0.92 |
The PASAPQ is a multi-item measure of inhalation device satisfaction and preference designed specifically for participants with asthma and chronic obstructive pulmonary disease. The PASAPQ includes a total of 14 device satisfaction items, including an overall satisfaction item. The total score was the sum of the 13 items related to performance and convenience domains (7 items for performance domain: Questions 1-5, 10-11, and 6 items for convenience domain: Questions 6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction.
| units on a scale | Stage 1: Empty Spiromax | Stage 1: Empty Turbohaler |
|---|---|---|
| Stage 1: Patient Satisfaction and Preference Questionnaire (PASAPQ) Total Score | 89.80 (18.37 to 100.00) | 85.71 (14.29 to 100.00) |
Composite score calculated as the sum of nurse observed errors and technology-observed errors.
| errors | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| Composite Endpoint: Stage 2: Total Number of Observed Errors (Nurse and Technology [Vitalograph Pneumotrac Spirometer]) | 0.50 ± 0.68 | 0.82 ± 1.10 |
| Errors | Stage 2: BF Spiromax | Stage 1: Symbicort Turbohaler |
|---|---|---|
| Stage 2: Number of Technology-Observed Errors (Vitalograph Pneumotrac Spirometer) | 0.01 ± 0.08 | 0.01 ± 0.08 |
Total number of device handling errors included HCP observed errors and technology observed errors.
| errors | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| Stage 2: Total Number of Handling Errors | 0.50 ± 0.68 | 0.82 ± 1.10 |
The difference in the number of handling errors identified after participant training using the patient device information leaflet at stage 1 and after 12 weeks of treatment (end of stage 2).
| Errors | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| Stage 2: Change in Handling Errors From Stage 1 to Stage 2 | -0.95 ± 1.72 | -2.01 ± 2.52 |
Treatment adherence was categorized (as less than or equal to 50%, 51%-70%, 71%-99%, and 100%) and compared across treatment groups using a chi-square test.
| Participants | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| ≤50% | 60 | 61 |
| 51-70% | 19 | 16 |
| 71-99% | 70 | 71 |
| 100% | 2 | 6 |
The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted forced expiratory volume in 1 second (FEV1) on a 7-point scale (0 to 6). The score is the mean of the first 6 questions (excluding the FEV1 question), generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.
| units on a scale | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| Change at Week 4 | -0.22 ± 0.83 | -0.33 ± 0.81 |
| Change at Week 8 | -0.20 ± 0.98 | -0.30 ± 1.04 |
| Change at Week 12 | -0.22 ± 0.95 | -0.36 ± 1.05 |
The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.
| units on a scale | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| Stage 2: Change From Baseline in 7-Item ACQ | -0.20 ± 0.78 | -0.31 ± 0.92 |
Time to treatment failure was defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection.
| days | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| Stage 2: Time to First Treatment Failure | 76.38 ± 21.42 | 73.95 ± 24.27 |
Severe asthma exacerbation was defined as a hospitalization or emergency room attendance for asthma, or an acute course of oral corticosteroids (OCS).
| Participants | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| 0 asthma exacerbation | 139 | 136 |
| 1 asthma exacerbation | 11 | 17 |
| 2 asthma exacerbation | 1 | 1 |
| ≥3 asthma exacerbations | 0 | 0 |
The impact of maintaining device mastery on time to treatment failure (defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection) was assessed by comparing the time to treatment failure for participants with and without device mastery. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.
| Days | Stage 2: BF Spiromax | Stage 1: Symbicort Turbohaler |
|---|---|---|
| Device mastery = Yes | 72.99 ± 22.38 | 75.93 ± 22.59 |
| Device mastery = No | 81.24 ± 19.11 | 71.69 ± 26.03 |
The impact of maintaining device mastery on asthma control was assessed by comparing the 7-item ACQ scores for participants with and without device mastery. The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.
| Units on a scale | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| Device mastery = Yes | 1.25 ± 1.05 | 1.35 ± 0.95 |
| Device mastery = No | 1.46 ± 0.97 | 1.37 ± 0.97 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
| Participants | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 113 | 119 |
Collected over Baseline up to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 2: BF Spiromax | 0/197 (0%) | 3/197 (1.5%) | 27/197 (13.7%) |
| Stage 2: Symbicort Turbohaler | 0/197 (0%) | 7/197 (3.6%) | 39/197 (19.8%) |
| Event | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| Chest painGeneral disorders | 0/197 | 2/197 |
| Angina pectorisCardiac disorders | 1/197 | 0/197 |
| Atrial flutterCardiac disorders | 0/197 | 1/197 |
| Atrioventricular blockCardiac disorders | 0/197 | 1/197 |
| Lower respiratory tract infectionInfections and infestations | 1/197 | 1/197 |
| Postoperative wound infectionInfections and infestations | 1/197 | 0/197 |
| Thermal burnInjury, poisoning and procedural complications | 0/197 | 1/197 |
| Renal failure acuteRenal and urinary disorders | 0/197 | 1/197 |
| Ovarian massReproductive system and breast disorders | 0/197 | 1/197 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/197 | 0/197 |
| Event | Stage 2: BF Spiromax | Stage 2: Symbicort Turbohaler |
|---|---|---|
| Lower respiratory tract infectionInfections and infestations | 16/197 | 29/197 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/197 | 12/197 |
Randomized analysis set included all randomized participants.
| Age, Continuous(years) | Empty Spiromax Followed by Empty Turbohaler | Empty Turbohaler Followed by Empty Spiromax | Total |
|---|---|---|---|
| Mean | 54.4 ± 13.8 | 53.1 ± 14.2 | 53.8 ± 14.0 |
| Sex: Female, Male(Participants) | Empty Spiromax Followed by Empty Turbohaler | Empty Turbohaler Followed by Empty Spiromax | Total |
|---|---|---|---|
| Female | 152 | 134 | 286 |
| Male | 91 | 108 | 199 |
| Race/Ethnicity, Customized(Participants) | Empty Spiromax Followed by Empty Turbohaler | Empty Turbohaler Followed by Empty Spiromax | Total |
|---|---|---|---|
| White | 238 | 235 | 473 |
| Black | 1 | 2 | 3 |
| Asian | 3 | 3 | 6 |
| Other | 1 | 2 | 3 |
Ran from May 2014 to primary completion in Mar 2015, 9 months.
Results were first posted in Mar 2024, 9 years after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 9 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Teva Branded Pharmaceutical Products R&D, Inc. →